Revenue
2024
2025
Pyxis Oncology, Inc. (PYXS)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | — | — | — | — |
| Research & development | $73.7M | $58.7M | $49.6M | $86.1M | $51.1M | $9.0M |
| Operating expenses | — | — | $82.2M | $123.5M | $69.7M | $12.9M |
| Operating income | −$84.4M | −$89.5M | −$82.2M | −$123.5M | −$69.7M | −$12.9M |
| EBITDAderived | −$79.9M | −$86.5M | −$80.3M | −$122.8M | −$69.1M | −$12.4M |
| Net income | −$79.6M | −$77.3M | −$73.8M | −$120.7M | −$76.0M | −$12.8M |
| Basic EPSper diluted share | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 | -$12.45 |
| Diluted EPSper diluted share | -$1.28 | -$1.32 | -$1.85 | -$3.65 | -$8.95 | -$12.45 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 21, 2025Form 4 · 10b5-1 | HUMPHREY RACHELDirector | SellCommon Stock | 13.9K | $1.03 | $14.3K | 81.3K |
| Apr 17, 2025Form 4 · 10b5-1 | HUMPHREY RACHELDirector | SellCommon Stock | 200 | $0.97 | $194.00 | 95.2K |
| Apr 14, 2025Form 4 · 10b5-1 | HUMPHREY RACHELDirector | SellCommon Stock | 1.4K | $0.97 | $1.4K | 95.4K |
| Nov 26, 2024Form 4 | Connealy Pamela AnnCFO & COO | BuyCommon Stock · indirect | 83.4K | $1.96 | $163.5K | 1.20M |
| Nov 26, 2024Form 4 | Connealy Pamela AnnCFO & COO | BuyCommon Stock · indirect | 5.5K | $2.00 | $10.9K | 1.12M |